mTOR inhibition induces compensatory, therapeutically targetable MEK activation in renal cell carcinoma.

mTOR inhibition induces compensatory, therapeutically targetable MEK activation in renal cell carcinoma.

Rapamycin derivatives allosterically targeting mTOR are currently FDA approved to treat advanced renal cell carcinoma (RCC), and catalytic inhibitors of mTOR/PI3K are now in clinical trials for treating various solid tumors. We sought to investigate the relative efficacy of allosteric versus catalyt...

Full description

Bibliographic Details
Main Authors: Sean T Bailey, Bing Zhou, Jeffrey S Damrauer, Bhavani Krishnan, Harper L Wilson, Aleisha M Smith, Mingqing Li, Jen Jen Yeh, William Y Kim
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4152178?pdf=render

Similar Items

Similar Items